QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response
30 May 2023
Breakthrough Therapy
The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment.
KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH). The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.
NPH is a condition characterized by disturbed cerebrospinal fluid (CSF) dynamics, which manifests as a clinical triad of difficulty in walking and balancing, urinary disturbances, and cognitive decline. Although the prevalence of NPH is around 2% among people older than 65 years, it is estimated to be widely under-detected due to the invasive and inaccessible nature of the diagnostic procedure. NPH is a progressive neurodegenerative condition, and its symptoms are often confused with other types of dementia or movement disorders such as Alzheimer's disease, vascular dementia, or Parkinson's disease. However, NPH is a treatable condition, particularly when detected in its early stages, through the implantation of a ventriculoperitoneal shunt.
The current diagnostic procedure for NPH involves a complex assessment, including cognitive evaluation, brain imaging (MRI or CT scan), and an evaluation of mobility before and after an invasive spinal CSF withdrawal (CSF tap test). This evaluation procedure requires specialized expertise and a dedicated facility, carrying a significant risk of complications. Furthermore, it fails to reliably determine which patients are most likely to benefit from VPS surgery.
While shunt surgery is highly effective in treating NPH, with over 85% of patients experiencing substantial clinical improvement, the complex diagnostic procedure remains a major barrier to accurate diagnosis. As a result, only about 20% of affected patients undergo shunt surgery.
The Delphi-MD system is a first-in-class medical device that provides physicians with accessible neurodiagnostic capabilities at any point of care, leading to improved brain health outcomes and better patient care. Delphi-MD was granted breakthrough designation by the FDA based on preliminary clinical data demonstrating its superiority over the current standard-of-care diagnostic procedure in accurately diagnosing NPH and predicting the effectiveness of shunt treatment.
This marks the second time that the Delphi-MD device has been granted a breakthrough designated medical device by the FDA. In June 2021, the system received this status for the detection of patients at risk for dementia and stroke, enabling the early identification of functional and structural brain abnormalities that indicate the early progression to stroke and dementia. Today's announcement significantly expands the value delivered by Delphi-MD to both clinicians and patients. The availability of an accurate, clinically objective neuronal function measurement system that streamlines the diagnosis process, improves treatment selection, enables earlier intervention, and most importantly, enhances the quality of life for those who need it the most.
"This second breakthrough designation status granted to Delphi-MD, focusing on NPH detection and treatment prediction is a major achievement and yet another reinforcement of our vision, providing a reliable tool for improved brain diagnosis and optimal personalized patient care." Said Dr. Iftach Dolev, CEO and Co-Founder of QuantalX.
"I am excited about the new Delphi-MD NPH indication, the NPH diagnostic procedure will become easy and accessible for the first time, and undetected and untreated patients will be able to benefit from an effective shunt (VPS) treatment." Said Dr. Rick Kuntz, Former Senior Vice President and President of Neuromodulation, Chief Medical and Scientific Officer at Medtronic.
About QuantalX
QuantalX is dedicated to providing better patient care and reducing healthcare systems' burden through early detection, differential diagnosis and treatment prediction of brain abnormalities by leveraging novel neurodiagnostic technology, the Delphi-MD device.
Media contact:
Adi Jacobson
[email protected]
Tel: +972502044934
SOURCE QuantalX
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.